Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Squamous Cell Carcinoma of Head and Neck
Open-data reference.
38 US clinical trials · 15 currently recruiting
Active & Recent Trials
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT04389632
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04895709
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Janssen Research & Development
NCT07276399
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Janssen Research & Development
NCT06385080
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
NCT06242470
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
University of California, San Francis
NCT06606028
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
Totus Medicines
NCT05683418
A Study of DM005 in Patients With Advanced Solid Tumors
Doma Biopharmaceutical（Suzhou）Co.
NCT06515990
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
University of Arkansas
NCT05952934
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
Massachusetts Eye and Ear Infirmary
NCT06744296
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
IO Biotech
NCT05280314
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Barbara Burtness
NCT05317000
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT07063212
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Johnson & Johnson Enterprise Innovation
NCT07219212
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
Brigham and Women's Hospital
NCT05553782
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Asher Biotherapeutics
NCT05653882
MicroRNA Markers in Head and Neck Cancers
University of Colorado, Denver
NCT04305366
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals
NCT04913337
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Nanobiotix
NCT03589339
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05215574
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
Transgene
NCT04183166
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05311618
HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer
University of Texas Southwestern Medical Center
NCT04403620
Pembrolizumab Plus Olaparib in LA-HNSCC
UNC Lineberger Comprehensive Cancer Center
NCT05366166
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
University of Chicago
NCT06110195
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
Wugen
NCT05674526
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
University of Wisconsin, Madison
NCT05816785
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
Rakuten Medical
NCT05182866
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
H. Lee Moffitt Cancer Center and Research Institute
NCT06236425
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Merck Sharp & Dohme
NCT04428151
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
Hoffmann-La Roche
NCT04665843
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
NCT04580485
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
TyrNovo
NCT04474470
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT03829436
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
Mural Oncology
NCT04144517
Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC
University of Colorado, Denver
NCT05053737
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company
NCT04601402
sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC
University of Colorado, Denver
NCT04091867
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 25 |
| Phase 2 | 9 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Squamous Cell Carcinoma of Head and Neck Trial Landscape
ClinicalTrials.gov lists 38 US studies indexed under Squamous Cell Carcinoma of Head and Neck, and 15 of those are currently open to recruitment — roughly 39% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Squamous Cell Carcinoma of Head and Neck shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 34 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Squamous Cell Carcinoma of Head and Neck is led by NGM Biopharmaceuticals with 3 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 38 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Squamous Cell Carcinoma of Head and Neck?
PlainTrial tracks 38 US clinical trials for Squamous Cell Carcinoma of Head and Neck, of which 15 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Squamous Cell Carcinoma of Head and Neck?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.